These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24013526)

  • 1. A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
    Huang WT; Chen HH; Yeh CH; Lu YC; Hwang WS; Huang JS; Chen CP; Lin PC; Uen WC; Lee YC; Wang HM; Wu HC; Chen JS; Kao RH; Huang CC; Jeng HH; Lin CJ; Hsieh RK
    J Investig Med; 2013 Oct; 61(7):1108-14. PubMed ID: 24013526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
    Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
    Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
    Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
    Wilke H; Glynne-Jones R; Thaler J; Adenis A; Preusser P; Aguilar EA; Aapro MS; Esser R; Loos AH; Siena S
    J Clin Oncol; 2008 Nov; 26(33):5335-43. PubMed ID: 18854570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.
    Loupakis F; Antoniotti C; Cremolini C; Zhang W; Yang D; Wakatsuki T; Bohanes P; Schirripa M; Salvatore L; Masi G; Ricci V; Graziano F; Ruzzo A; Benhaim L; Marmorino F; Ning Y; El-Khoueiry R; Falcone A; Lenz HJ
    Pharmacogenomics J; 2014 Aug; 14(4):322-7. PubMed ID: 24513691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer.
    Jehn CF; Böning L; Kröning H; Pezzutto A; Lüftner D
    Eur J Cancer; 2014 May; 50(7):1269-75. PubMed ID: 24503027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.